Titan Pharmaceuticals Inc (TTNP)

$4.98

+0.08

(+1.63%)▲

Market is closed - opens 7 PM, 14 Oct 2024

Performance

  • $4.97
    $5.04
    $4.98
    downward going graph

    0.2%

    Downside

    Day's Volatility :1.45%

    Upside

    1.25%

    downward going graph
  • $0.31
    $14.80
    $4.98
    downward going graph

    93.68%

    Downside

    52 Weeks Volatility :97.87%

    Upside

    66.35%

    downward going graph

Returns

PeriodTitan Pharmaceuticals IncIndex (Russel 2000)
3 Months
6.64%
0.0%
6 Months
-31.38%
0.0%
1 Year
-45.87%
0.0%
3 Years
-86.01%
-21.1%

Highlights

Market Capitalization
4.6M
Book Value
$4.37
Earnings Per Share (EPS)
-6.75
PEG Ratio
0.0
Wall Street Target Price
7.0
Profit Margin
0.0%
Operating Margin TTM
-237633.33%
Return On Assets TTM
-172.63%
Return On Equity TTM
-368.99%
Revenue TTM
3.0K
Revenue Per Share TTM
0.0
Quarterly Revenue Growth YOY
-100.0%
Gross Profit TTM
-4.4M
EBITDA
-7.1M
Diluted Eps TTM
-6.75
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
0.0
EPS Estimate Next Year
0.0
EPS Estimate Current Quarter
0.0
EPS Estimate Next Quarter
0.0

Analyst Recommendation

Sell
    0
    0%Buy
    50%Hold
    50%Sell
Based on 6 Wall street analysts offering stock ratings for Titan Pharmaceuticals Inc(by analysts ranked 0 to 5 stars)
Based on 6 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
00
00
00
Hold
3
3
3
Sell
3
3
3

Analyst Forecast

What analysts predicted

Upside of 40.56%

Current $4.98
Target $7.00

Technicals Summary

Sell

Neutral

Buy

Titan Pharmaceuticals Inc is currently in a neutral trading position according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Titan Pharmaceuticals Inc
Titan Pharmaceuticals Inc
-10.11%
-31.38%
-45.87%
-86.01%
-97.7%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
-11.94%
13.03%
20.97%
85.64%
232.53%
Novo Nordisk A/s
Novo Nordisk A/s
-12.38%
-3.12%
17.52%
138.65%
361.43%
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
7.18%
92.5%
69.12%
39.45%
259.26%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
-0.75%
21.23%
29.84%
165.64%
177.5%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Titan Pharmaceuticals Inc
Titan Pharmaceuticals Inc
NA
NA
0.0
0.0
-3.69
-1.73
NA
4.37
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
26.88
26.88
1.38
45.01
0.17
0.08
NA
261.41
Novo Nordisk A/s
Novo Nordisk A/s
40.83
40.83
1.8
3.37
0.89
0.23
0.01
25.24
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
NA
NA
-0.49
-2.38
-15.01
0.02
NA
-0.02
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
32.84
NA
0.58
0.33
-0.03
0.13
NA
57.26
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Titan Pharmaceuticals Inc
Titan Pharmaceuticals Inc
Sell
$4.6M
-97.7%
NA
0.0%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$110.1B
232.53%
26.88
32.04%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$523.9B
361.43%
40.83
34.84%
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
Buy
$36.5B
259.26%
NA
-3.11%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$124.3B
177.5%
32.84
-4.74%

Insights on Titan Pharmaceuticals Inc

  • Increasing Revenue

    Revenue is up for the last 3 quarters, 1.0K → 81.0K (in $), with an average increase of 85.0% per quarter

  • Decreasing Net Profit

    Netprofit is down for the last 2 quarters, -1.06M → -2.09M (in $), with an average decrease of 97.5% per quarter

  • Vs ALNY

    In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 69.1% return, outperforming this stock by 115.0%

  • Vs VRTX

    In the last 3 years, Vertex Pharmaceuticals Incorporated has given 39.4% return, outperforming this stock by 125.4%

Institutional Holdings

  • BB&T Corp.

    3.42%

  • Tower Research Capital LLC

    0.08%

  • Mcf Advisors, LLC

    0.02%

Company Information

titan pharmaceuticals inc. is developing proprietary therapeutics primarily for the treatment of serious medical disorders. the company's lead product is probuphine®, the first and only commercialized treatment of opioid dependence to provide continuous, around-the-clock blood levels of buprenorphine for six months following a single procedure. it was approved by the u.s. food and drug administration in may 2016 and is being commercialized in the u.s. by partner braeburn pharmaceuticals. probuphine employs titan's proprietary drug delivery system proneura™, which is capable of delivering sustained, consistent levels of medication for up to 12 months. the proneura technology has the potential to be used in developing products for treating other chronic conditions such as parkinson's disease and hypothyroidism, where maintaining consistent, around-the-clock blood levels of medication may benefit the patient and improve medical outcomes.

Organization
Titan Pharmaceuticals Inc
Employees
4
CEO
Dr. Katherine L. Beebe-DeVarney Ph.D.
Industry
Health Technology

Discover More

FAQs